US 12,377,101 B2
Combination therapies
James Gail Christensen, San Diego, CA (US); Lars Daniel Engstrom, Carlsbad, CA (US); Peter Olson, San Diego, CA (US); and Ruth Wei Aranda, San Diego, CA (US)
Assigned to MIRATI THERAPEUTICS, INC., Princeton, NJ (US)
Appl. No. 17/275,181
Filed by Mirati Therapeutics, Inc., San Diego, CA (US)
PCT Filed Dec. 5, 2019, PCT No. PCT/US2019/064707
§ 371(c)(1), (2) Date Mar. 10, 2021,
PCT Pub. No. WO2020/118066, PCT Pub. Date Jun. 11, 2020.
Claims priority of provisional application 62/775,628, filed on Dec. 5, 2018.
Prior Publication US 2022/0079947 A1, Mar. 17, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 31/497 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/497 (2013.01); A61P 35/00 (2018.01)] 11 Claims
 
1. A method of treating KRAS G12C-associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor, wherein said KRas G12C inhibitor is:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.